R289

R289 is an oral prodrug of R835, a potent and selective dual inhibitor of interleukin-1 receptor-associated kinase 1 (IRAK1) and IRAK4. It is being developed by Rigel Pharmaceuticals for the treatment of myelodysplastic syndromes (MDS), particularly in patients with lower-risk MDS who are relapsed or refractory to prior therapies. The drug works by blocking inflammatory cytokine production in response to toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) family signaling, targeting the pro-inflammatory environment in bone marrow that contributes to persistent cytopenias in these patients. Preclinical studies have demonstrated its ability to inhibit inflammatory pathways implicated in MDS pathogenesis. Clinical data from an ongoing Phase 1b study show preliminary evidence of hematologic responses, including transfusion independence, with a favorable safety profile[1][2][3][5][8].